Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 28 May 2021
FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma
28 May 2021 - Today, the FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics), a kinase inhibitor for adults ...
Posted by Michael Wonder on 28 May 2021
First COVID-19 vaccine approved for children aged 12 to 15 in EU
28 May 2021 - EMA’s CHMP has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use ...
Posted by Michael Wonder on 28 May 2021
FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy
28 May 2021 - Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients ...
Posted by Michael Wonder on 28 May 2021
Verrica Pharmaceuticals announces extension of FDA review period of its NDA for VP-102 for the treatment of molluscum contagiosum
28 May 2021 - Prescription Drug User Fee Act goal date extended by three months to 23 September 2021. ...
Posted by Michael Wonder on 28 May 2021
NICE green lights Tremfya to treat active psoriatic arthritis
28 May 2021 - Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s NICE for the ...
Posted by Michael Wonder on 28 May 2021
U.S. Food and Drug Administration approves Bristol Myers Squibb’s Zeposia (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis
27 May 2021 - Bristol Myers Squibb is committed to making Zeposia accessible to appropriate patients who need it through the ...
Posted by Michael Wonder on 28 May 2021
Tagrisso approved in the EU for the adjuvant treatment of patients with early stage EGFR mutated lung cancer
28 May 2021 - Approval based on unprecedented results from the ADAURA Phase 3 trial where Tagrisso reduced the risk ...
Posted by Michael Wonder on 28 May 2021
Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
25 May 2021 - Novartis today announced that the US FDA has granted fast track designation for sabatolimab (MBG453) for the ...
Posted by Michael Wonder on 28 May 2021
Post-market review of opiate dependence treatment program medicines
28 May 2021 - On 24 March 2021 it was announced the Department of Health will conduct a post-market review ...
Posted by Michael Wonder on 27 May 2021
Amazon looking at opening pharmacy stores in US
26 May 2021 - Amazon is considering the launch of brick and mortar pharmacies in the United States, Insider reported ...
Posted by Michael Wonder on 27 May 2021
NASP applauds the Introduction of bipartisan legislation to reduce drug costs and support medication access for seniors with life-threatening specialised conditions
27 May 2021 - This week, a bipartisan group of lawmakers in the U.S. House and Senate introduced legislation to rein ...
Posted by Michael Wonder on 27 May 2021
Insufficient data on use of inhaled corticosteroids to treat COVID-19
27 May 2021 - EMA’s COVID-19 taskforce is advising health care professionals that there is currently insufficient evidence that inhaled ...
Posted by Michael Wonder on 27 May 2021
Ireland an outlier without access to new cell and gene therapy, report says
27 May 2021 - Upfront costs high but treatments may cut long-term expense and boost patient results. ...
Posted by Michael Wonder on 27 May 2021
Democrats promised to lower drug prices, but plans are sputtering
26 May 2021 - With control of Congress and the White House, Democrats have an opportunity to bring down prescription ...
Posted by Michael Wonder on 27 May 2021
FDA approves Biohaven's Nurtec ODT (rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
27 May 2021 - Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine. ...